ImClone Systems has announced the initiation of enrollment of patients with androgen-independent prostate cancer (AIPC) in a Phase II clinical trial with either IMC-A12 or IMC-1121B plus mitoxantrone and prednisone. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: cancer, IMC-1121B, IMC-A12, news, prostate, update | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 